Endothelial nitric oxide synthase (eNOS) and the nitrate-nitrite-nitric oxide pathway (eNOS/NO pathway)

Endothelial nitric oxide synthase (eNOS), or NOS3, is a calcium-dependent enzyme primarily expressed in the vascular endothelium that converts L-arginine into nitric oxide (NO), a key regulator of vascular homeostasis (UniProt P29474). The nitrate-nitrite-nitric oxide pathway represents a secondary, oxygen-independent route for NO production, where dietary or endogenous nitrate is reduced to nitrite by commensal bacteria and subsequently to NO by various reductases, particularly during hypoxia (Lundberg et al., Nat Rev Drug Discov, 2008). Together, these pathways maintain systemic blood pressure, inhibit platelet activation, and protect against atherosclerosis by ensuring adequate NO bioavailability (Förstermann & Sessa, Eur Heart J, 2012). Dysfunction in eNOS, often termed "uncoupling," leads to the production of reactive oxygen species instead of NO, contributing to endothelial dysfunction and cardiovascular diseases like hypertension and heart failure (Moncada & Higgs, NEJM, 1993). Pharmacological interventions include organic nitrates, inorganic nitrite/nitrate supplements, and eNOS activators like nebivolol, all aimed at restoring NO levels to improve blood flow and reduce vascular resistance (Bryan et al., Free Radic Biol Med, 2007).

Other names

NOS3Nitric oxide synthase 3Constitutive nitric oxide synthaseL-arginine-NO pathwayEndothelial NOS

Drugs targeting this pathway act by providing exogenous sources of nitric oxide (NO donors), enhancing the enzymatic activity or expression of eNOS, or utilizing the alternative nitrate-nitrite reduction pathway to bypass eNOS dysfunction, ultimately increasing cyclic guanosine monophosphate (cGMP) levels to induce vasodilation (Lundberg et al., 2008; Förstermann & Sessa, 2012).